ReviewIUBMB life2010
PELP1: A novel therapeutic target for hormonal cancers.
Review in IUBMB life, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.Breast cancer research and treatment · 2023Article
- A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.Cancer research · 2022Article
- SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.Breast cancer research : BCR · 2022Article
- Inflammation-induced PELP1 expression promotes tumorigenesis by activating GM-CSF paracrine secretion in the tumor microenvironment.The Journal of biological chemistry · 2022Article
- Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.Molecular oncology · 2021Article
- Article
- PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer.Oncotarget · 2020Article
- The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.Cancer research and treatment · 2019Article
- STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment.International journal of molecular sciences · 2018Review
- PELP1: a key mediator of oestrogen signalling and actions in the brain.Journal of neuroendocrinology · 2018Review
- Article
- Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.PloS one · 2016Article
- Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation.Journal of mammary gland biology and neoplasia · 2015Review
- Article
- PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.Cancer research · 2014Article
- Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.Oncogene · 2014Article
- Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.Molecular cancer therapeutics · 2014Article
- PELP1 oncogenic functions involve CARM1 regulation.Carcinogenesis · 2013Article
- The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.BMC cancer · 2013Article
- Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.Nature communications · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent studies implicate that the estrogen receptor (ER) coregulator proline-, glutamic acid-, and leucine-rich protein (PELP) 1 as playing critical roles in ER-genomic, ER-nongenomic, and ER-signaling cross talk with growth factor signaling pathways. PELP1 expression is deregulated in hormonal cancers and recent studies further elucidated the molecular mechanisms by which PELP1 regulates hormone therapy response. Although PELP1 is important for normal functions of the ER, the possibility to target ER-PELP1 axis appears to be an effective strategy for preventing hormonal carcinogenesis and therapy resistance. Thus, PELP1 may be useful as prognostic marker for hormonal cancers and PELP1 signaling may be useful to generate targeted therapeutics to overcome hormonal therapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.